NCT07278973 Hemodiafiltration Versus Hemodialysis in Older People
| NCT ID | NCT07278973 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AUB Santé |
| Condition | Hemodialysis |
| Study Type | INTERVENTIONAL |
| Enrollment | 62 participants |
| Start Date | 2026-02-19 |
| Primary Completion | 2026-12-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 62 participants in total. It began in 2026-02-19 with a primary completion date of 2026-12-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will compare the impact of two hemodialysis techniques on fatigue and post-dialysis recovery time in patients aged 85 years and older. These two techniques are high-flux hemodialysis (HD) and hemodiafiltration (HDF). Patients will receive the treatment over two periods: if period 1 is HD then period 2 will be HDF. Every patient will be his/her own control, this is why it is called cross-over. Each period will last three months. Between the two periods, patients will receive a traditional low-flux hemodialysis. These two techniques are widely used worldwide and their side-effects are well-known and do not put the patients at risk. HDF has been shown to improve survival in patients with a mean age of 58 years. But a previous study from the investigators' group showed that HDF causes a prolonged recovery time in older patients. This randomized trial aims to elucidate this question.
Eligibility Criteria
Inclusion Criteria: * Signed and dated informed consent * Age \>84 years * Diagnosed with kidney failure * On maintenance hemodialysis \>3months * Willing to have a dialysis session of 3.5 to 4-hour duration, three times a week * Has a reliable vascular access * Is covered by the health insurance Exclusion Criteria: * Patients with cognitive impairment (assessed with a mini-test if needed) * Hospitalized at inclusion * Have difficulties with French speaking * Terminally ill with life expectancy\<3 months * With active cancer
Contact & Investigator
Mabel Aoun, M.D., M.P.H.
STUDY CHAIR
AUB SANTE
Frequently Asked Questions
Who can join the NCT07278973 clinical trial?
This trial is open to participants of all sexes, aged 85 Years or older, studying Hemodialysis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07278973 currently recruiting?
Yes, NCT07278973 is actively recruiting participants. Contact the research team at aounmabel@yahoo.fr for enrollment information.
Where is the NCT07278973 trial being conducted?
This trial is being conducted at Bretagne, France, Grabels, France, Le Mans, France, Paris, France.
Who is sponsoring the NCT07278973 clinical trial?
NCT07278973 is sponsored by AUB Santé. The principal investigator is Mabel Aoun, M.D., M.P.H. at AUB SANTE. The trial plans to enroll 62 participants.